Dr. John Raymond Receives National Acclaim
On February 1, Dr. John Raymond was in Washington to receive the NIH Center for Scientific Review’s (CSR) top honor – the Marcy Speer Outstanding Reviewer Award. Those of us who know Dr. Raymond the best know that this national acclaim is justified. He spends an incredible amount of time in this selfless activity or reviewing others’ grants. His work is one thing, but the quality of his reviews and his leadership of study sections are additional reasons that the award has been given to the best person.
In an average year, about 16,000 reviewers volunteer about 150,000 days to assess the scientific merit of approximately 56,000 applications. Their scientific evaluations help NIH invest more than $20 billion in the most promising research grants, paving the path to biomedical breakthroughs that improve public health and save lives.
"Dr. John Raymond personifies the humbling dedication of our reviewers, who give so much to advance science and health here and around the world," said CSR Director Dr. Toni Scarpa. "He has served at nearly 100 review meetings, demonstrating a tireless commitment to fair and rigorous reviews."
In addition to John’s tireless efforts to enhance research on this campus as Provost, he has been a leader for the NIH scientific review process. He served a 4-year term as a charter member of CSR's Molecular, Cellular and Developmental Neurosciences-5 study section. When this study section evolved into the Molecular Neuropharmacology and Signaling study section, he took on the role of chair for two years to help it get established. Most recently, Dr. Raymond began another 4-year term on CSR’s Pathobiology of Kidney Disease study section.
The Marcy Speer Award recognizes scientists who demonstrate extraordinary commitment to CSR peer review groups making it possible for NIH to fund the best applications, and, ultimately, improve public health. The award's namesake exemplified this commitment by continuing to review grants during her treatment for breast cancer, and extending her term as a regular member of one of CSR's genetics review panels to make up for meetings she missed during chemotherapy. She died Aug. 4, 2007.
Congratulations, Dr. Raymond on this extraordinary honor.